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Breaching host defenses in the urinary tract
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Abstract
The sterility of the urinary tract is maintained by a variety of host mechanisms that prevent bacterial
colonization and survival. The innate immune system encompasses physical barriers to infection
as well as more specific soluble and cellular mediators of defense. If the mucosal barrier is breached,
a rapid, effective response leading to the eradication of pathogenic microorganisms is elicited before
they can cause significant injury. However, uropathogenic bacteria have developed a range of
virulence factors that enable them to overcome these innate defense mechanisms and therefore
persist within the urinary tract. In particular, recent evidence suggests that bacteria can actually
utilize the host’s own immune system to aid colonization. By hijacking host proteins, the bacteria
are able to gain access to environments that are both rich in nutrients and protected for the
bactericidal effects of host immunity. Fortunately, the balance between host defense and infection
usually lies in favor of the host, but only minor shifts result in the development of clinical infection.
We are moving into an era of greater understanding of the important factors that influence this
balance between host and pathogen. In this article, we review the current understanding of the
factors that influence the development of urinary tract infection. Understanding these mechanisms
may contribute to the development of strategies to combat this common infection.
Key words: Bacteriuria/microbiology, Epithelial cells, Escherichia coli/pathogenicity, Urinary tract infections/
therapy, Virulence
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R E V I E W
A R T I C L E
INTRODUCTION
Urinary tract infection (UTI) is a major cause of
morbidity and mortality. It has been estimated that there
are more than 150 million episodes of UTI per year on a
global basis (1). The majority of these infections occur
in women with 40% to 50% of women developing a UTI
at some stage in their lifetime (2). The incidence of
pyelonephritis is less documented. However, studies
from the United States estimate that at least 250 000
episodes of acute pyelonephritis occur annually among
adult women (3), resulting in as many as 100 000
hospitalizations (4). In addition, chronic pyelonephritis
has been reported as the cause of renal failure in 15% to
25% of children and young adults, requiring renal
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thereby preventing access to the epithelium and
facilitating their removal by the voiding process. In the
kidney, the cells of the ascending limb of the loop of
Henle secrete Tam-Horsfall mucoprotein that also acts
as an antiadherence factor by binding to specific
structures on the bacterial surface and preventing
adhesion to epithelial cells by competitive inhibition.
Additionally, urine contains microbicidal substances
including the enzyme lysozyme that specifically cleaves
the cell wall of gram-positive bacteria. If bacteria do
manage to evade the urine flow and antimicrobial
substances and penetrate the mucous membrane, then
bladder cells have another strategy to prevent colon-
ization, namely suicide. In response to infection in the
bladder, epithelial cells internalize bacteria, then undergo
a rapid apoptosis-like process involving DNA frag-
mentation and activation of proteolytic enzymes. This
leads to shedding of the infected cells and their removal
from the urinary tract (8).
If these primary defenses are breached, more specific
innate immune responses are initiated, including
recruitment of phagocytes and complement activation.
These are fast-acting, relatively nonspecific responses,
that provide an essential challenge to invading pathogens.
The complement system is a major part of the innate
immune response, providing a rapid defense against a
wide range of invading microorganisms by means of
direct lysis, production of proinflammatory mediators,
and C3 opsonization. The system consists of ap-
proximately 30 serum and membrane-bound proteins and
constitutes nearly 10% of the total serum protein, forming
a cascade that amplifies the initial response (Fig. 1). The
cascade can be activated by three distinct pathways
converging on the pivotal complement protein C3. The
outer membrane of E. coli contains lipopolysaccharide
(LPS), which can activate all three pathways of com-
plement. Direct killing of microorganisms by com-
plement is achieved by insertion of the terminal
membrane attack complex (MAC) into the lipid bilayer
of the target cell. The formation of MAC creates pores
in the cell surface through which solutes can diffuse,
leading to osmotic lysis of the bacterium.
The opsonization of bacteria by complement enhances
their removal by phagocytes and is probably the principal
replacement (5). The bacteria that cause pyelonephritis
are usually derived from the host’s own bowel flora,
entering the bladder via the ascending urethral route. In
more than 80% of the cases, the causative agent is
Escherichia coli, but other bacteria including Proteus
mirabilis, Klebsiella aerogenes, and Enterococci have
also been implicated (6).
THE HOST INNATE DEFENSE
Although the urinary tract is clearly a target for microbial
infection, generally the urine remains sterile because of
the presence of highly efficient defense mechanisms. The
first lines of host defense to urinary pathogens are the
unidirectional flow of urine and the presence of
antimicrobial factors in the urine (Table 1). The flow of
urine from the kidney by ureteric peristalsis, and from
the bladder by periodic detrusor contraction, eliminates
bacteria from the epithelial surfaces and constitutes the
main defense mechanism of the urinary tract (7). In the
lower urinary tract, additional protection is provided by
the secretion of glycosaminoglycans by bladder
transitional cells. This forms a surface layer of mucin
that acts as an antiadherence factor, trapping bacteria,
Table 1. Primary antimicrobial mechanisms in the urinary tract.
Mechanism Action
Urine flow Physical removal of bacteria from the urinary tract
Mucous Traps and prevents bacterial adherence to the epithelium
Tam-Horsfall protein Competitive inhibition of bacterial binding to the epithelium
Lysozyme Cleaves cell wall components, killing bacteria
Exfoliation Removal of infected cells from the urinary tract
Figure 1. Outline of the complement system. The complement
system can be activated by the classical, MBL, or alternative
pathways. The pathways converge to cause activation of C3 and
subsequent formation of the MAC.
B = factor B; C = complement protein; D = factor D; MAC =
membrane attack complex; MASP = MBL-associated serine
protease; MBL = mannan-binding lectin
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method of eliminating microorganisms by complement.
It is mediated primarily by split products of C3, and to a
much lesser extent, C4. These are recognized by
complement receptors (CRs) 1 and 3 on phagocytic cells,
which, along with Fc receptors, are responsible for
phagocytosis of pathogens. The activation of complement
also results in the cleavage of complement proteins C3
and C5 to yield small highly biologically active fragments
C3a and C5a. These peptides have wide-ranging effects,
including the promotion of smooth muscle contraction,
retraction of endothelial cells, and the release of
histamine by mast cells and basophils. Furthermore, there
are specific receptors on phagocytes for C5a and C3a
that, when engaged, cause activation and directed cellular
movement (chemotaxis) of the cells to sites of infection.
The importance of the complement system in the
eradication of bacteria is demonstrated by a deficiency
of the components. A deficiency in any one of the
complement components leads to increased susceptibility
to bacterial infections such as Neisseria, Staphylococcus,
and Streptococcus. The type of infection encountered
depends on the specific complement component
deficiency. The level of complement production as a
result of genetic polymorphism may therefore determine
an individual’s susceptibility to infection. For example,
low serum levels of mannan-binding lectin have recently
been shown to predispose patients to serious infections
after chemotherapy.
There are two types of specialized phagocytic cells,
macrophages and neutrophils, both of which are derived
from common stem cells within the bone marrow.
Neutrophils and macrophages respond to bacterial stimu-
li by chemotaxis along a concentration gradient of
chemotactic molecules including anaphylatoxins (C3a
and C5a), leukotriene B4, interleukin-8 (IL-8),
phospholipids, and peptides derived from bacteria or
damaged cells. Phagocytes can bind bacteria via specific
sugar residues such as mannose. However, recognition
is greatly enhanced if the bacteria are opsonized with
antibody or C3 as described above. After recognition,
microorganisms are ingested into phagosomes that then
fuse with lysosomal granules to form a phagolysosome
in which the microorganisms are killed (Table 2).
Neutrophils are generally the first cellular components
to respond to infection and are essential in the defense
against UTI. They migrate from the circulation across
the endothelium and into the tissues within seconds of
the recognition of a chemotactic stimulus. Interleukin-8
receptor-deficient mice fail to recruit neutrophils to the
site of infection. Consequently, the mice are extremely
susceptible to UTI, showing impaired bacterial clearance
from the kidneys and bladder during the early phase of
infection and subsequently develop severe disease (9).
Lipopolysaccharide is released from the surface of all
gram-negative bacteria during growth and is recognized
via toll receptors on macrophages and neutrophils. After
engagement of LPS with toll receptors, the cells become
activated and release cytokines such as tumor necrosis
factor, interferon-γ, and IL-1, providing a link to the
adaptive immune response. The importance of the LPS-
induced response is highlighted in mice that have
defective LPS signaling caused by mutations in the toll
gene. These low-responder mice have an impaired
inflammatory response and lack the ability to clear E.
coli from their kidneys after ascending UTI. Mutations
in the toll genes may therefore alter susceptibility to
gram-negative infection or affect its clinical outcome.
ADAPTIVE IMMUNITY
If the organism is able to evade innate immune
mechanisms and persist within the urinary tract, the
adaptive immune response will ensue, including both
humoral and cellular responses. Binding of antibody to
pathogens leads to their removal by preventing at-
tachment of the bacteria to cells and promoting bacterial
phagocytosis and lysis. Immunoglobulin (Ig) A
antibodies have a particular role in preventing bacterial
infection of mucosal surfaces. Although studies have
found no difference in the urinary IgA titers between
children with recurrent UTI compared with controls,
children that had been breast-fed were found to have a
reduced incidence of UTI and this corresponded to higher
titers of urinary IgA (10). How urinary IgA protects
against infection is unclear, IgA secretion in the urinary
space may be important in preventing the attachment of
bacteria to the host cell (11). Other studies have suggested
a role for IgA in reducing bacterial translocation across
renal epithelial monolayers (12). A greater understand-
ing of the function of urinary antibodies could guide
strategies to develop vaccines against this disease.
Table 2. Mechanisms of killing bacteria by phagocytes.
Mechanism Products
Acidification pH 3-4
Enzymes Lysozyme
Acid hydrolases
Neutral proteases
Microbicidal peptides Defensins
Nutrient-binding proteins Lactoferrin
Vitamin B12 binding protein
Cytotoxic oxygen compounds Hydrogen peroxide
Singlet oxygen
Hydroxyl radical
Hypohalite
Cytotoxic nitrogen compounds Nitric oxide
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A role for T cells in UTI is even less well defined.
Infection studies in animal models have shown that T-
cell-deficient nude mice are no more susceptible to renal
infection compared with normal mice. However, the
duration of the infection is significantly longer (13). It is
likely that, in the initial stages of infection, T cells have
a very limited role in host defense; but as the cellular
response develops, they become crucial in the eradication
of bacteria from the kidneys. The adaptive immune
response can take up to a week to develop. Therefore,
the host is initially dependent on the innate immune
response to provide early defense against rapidly
multiplying microorganisms.
BACTERIAL STRATEGIES TO
ENHANCE INFECTIVITY
Uropathogenic bacteria, in particular E. coli, have
evolved a range of virulence factors that allow them to
counteract the host defenses and specifically colonize
and persist within the urinary tract. The virulence factors
most commonly associated with uropathogenic
organisms include serum resistance, production of toxins
such as hemolysin and colony necrotizing factor, and
the possession of adhesive fimbriae (Table 3). Bacterial
fimbriae are hair-like structures that bind glycoprotein
or glycolipid on uroepithelial cells, enabling the bacteria
to attach to the epithelium and persist within the urinary
tract. A typical bacterium can have as many as 100 to
500 fimbriae including many antigenically distinct types
(Fig. 2) (14). The most common fimbrial proteins
associated with E. coli UTIs are type 1, P, and Dr
fimbriae.
Type 1 fimbriated bacteria bind to mannose residues via
an adhesive tip protein called FimH. Type 1 fimbriae-
mediated adhesion is mostly associated with colonization
of the lower urinary tract where the bacteria bind to
mannose residues present on proteins called uroplakins
coating bladder epithelium (15). Studies in mice have
shown that bacteria lacking the FimH domain are unable
to bind to the bladder epithelium and anti-FimH antibody
blocks in vitro attachment of E. coli to bladder cells. A
vaccine based on the FimH domain provided protection
against bladder colonization in studies in both mice and
monkeys (16,17). Because colonization of the lower
urinary tract is a prerequisite for upper UTI, this raises
Table 3. Major virulence factors of uropathogenic bacteria.
Factor Action
Type 1 fimbriae Promotes adhesion in the lower urinary tract by binding to mannose residues on bladder epithelium
P fimbriae Promotes adhesion in the upper urinary tract by binding to Galα1, 4Gal residues on renal epithelial cells
Dr fimbriae Promotes recurrent infection; mechanism unknown
Capsule Physically prevents phagocytosis by neutrophils and macrophages
LPS Prevents complement-mediated lysis by deflecting activation
CNF Impairs neutrophil response; mechanism unknown
Hemolysin Target cell lysis, source of iron
Figure 2. E. coli fimbrial adhesion. Electron microscopy of
pyelonephritic E. coli. (A) Hair-like bacterial fimbriae protrude from
the surface of a negatively stained human isolate. (B) Bacteria
use these fimbriae to adhere to the surface of cultured human
proximal tubular cells.
A
B
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the possibility of not only a vaccine against cystitis, but
also protection against pyelonephritis.
P fimbriae are so called because they specifically adhere
to P blood group antigens on human erythrocytes.
Patients with the rare blood group P2 phenotype lack
these antigens and are therefore less susceptible to UTI
with E. coli. In contrast, susceptibility to UTI has been
linked to the P1 blood group (18). P fimbriae are found
on approximately 94% of E. coli strains causing
pyelonephritis compared with only 19% of isolates from
patients with cystitis and 14% of isolates from cases of
asymptomatic bacteriuria (19). Inoculation of a mixture
of type 1 and P fimbriated E. coli into mice results in
localization of type 1 fimbriated bacteria to the bladder
and P fimbriated bacteria to the kidneys (20). In the
human kidney, receptors for P fimbriae have been
identified on proximal tubular, distal tubular, and
collecting duct epithelium (21). P fimbrial-mediated
binding to the renal epithelium increases the bacterial
persistence within the kidney and therefore facilitates
infection.
The Dr family of fimbriae is specific for the Dr blood
group antigen and is expressed by 25% to 50% of E. coli
isolated from children with UTI (22). The expression of
the Dr fimbriae by E. coli has been suggested to increase
the risk of recurrent UTI (23). Dr fimbriae were originally
identified by their agglutination of human erythrocytes
expressing the Dr blood group antigen and the inability
to agglutinate Dr (a-) erythrocytes (24), a rare phenotype
of the Cromer blood group system in which the Dr
antigen is not expressed. The receptor for Dr blood group
adhesins has been identified as the complement regu-
latory protein decay accelerating factor (DAF) (25).
The bacterial surface is a potent activator of the
complement system resulting in bacterial eradication
through promotion of phagocytosis or direct lysis.
However, the majority of pathogens that cause UTI are
resistant to the bactericidal effects of serum. The structure
of the bacterial cell surface is important in this evasion
process. Some bacteria possess a thick peptidoglycan
layer that prevents insertion of the MAC into the cell
membrane. Gram-negative bacteria such as E. coli also
possess LPS molecules on their surface. The LPS
molecule activates complement but does so at a site away
from the bacterial outer membrane. Therefore, MAC
cannot effectively insert into the bacterial membrane,
and osmotic lysis does not occur. Some bacteria are also
able to avoid phagocytosis by possession of a surface
capsule.
Cytotoxic necrotizing factor (CNF) is a bacterial toxin
produced by 40% of uropathogenic E. coli strains,
suggesting that it may have a role in UTI (26). The
expression of CNF increases bacterial resistance to
killing by neutrophils (27) and decreases epithelial
transmigration of neutrophils to sites of infection (28).
However, evidence for a role for CNF in UTI is not
absolute and may be an effect of genetic linkage to
hemolysin (29). Hemolysin is another bacterial toxin that
is secreted by E. coli. It acts by irreversibly inserting
into eukaryotic membranes, creating a pore of about 2
nm (30). The pore forms a water-filled channel, leading
to osmotic lysis of the cell. Hemolytic strains of E. coli
are more prevalent among uropathogenic isolates. Cross-
sectional studies of patients with pyelonephritis have
reported hemolytic activity in 30% to 60% of isolates
compared with only 5% to 15% of fecal E. coli from
healthy controls (31). Among the hypotheses presented
to explain the role of hemolysin in clinical disease is
that it provides access to a source of intracellular iron
where it would otherwise be scarce. Because sufficient
iron is present in the urine to support the growth of E.
coli, hemolysin production would be most significant
during tissue-invasive infection. However, more recent
studies have proposed that hemolysin has a more direct
role in pyelonephritis by causing death of the target cell
(32).
THE EPITHELIAL RESPONSE
The epithelium is the first physical barrier encountered
by uropathogenic bacteria. It is capable of producing a
range of signaling molecules and antimicrobial
substances to prevent bacteria from traversing the
epithelium and causing infection in other tissues. The
cells of the epithelium secrete lytic enzymes such as
lysozyme and nutrient-binding proteins such as
lactoferrin. They also secrete smaller bactericidal
products known as defensins (33). Defensins are 3 to 4
kDa cationic proteins that insert into the phospholipid-
rich outer membrane of bacteria, creating pores that result
in osmotic lysis of the bacterium. Defensins have a wide
range of antimicrobial activity against bacteria, viruses,
and fungi. Although neutrophils are the primary source,
other cells including intestinal Paneth cells and urogenital
epithelial cells also produce defensins. In the kidneys,
the expression of human β defensin-2 has been
demonstrated in the epithelium of the loops of Henle,
the distal tubules, and the collecting ducts, and greatly
exceeds the concentrations found in other organs and
tissues (34). Other defensins are produced by phagocytic
cells that use them to kill ingested microbes. In addition
to direct lysis, defensins also attract dendritic cells and
memory T cells, thereby signaling the adaptive immune
response to sites of infection. The most abundant
signaling molecules, however, are cytokines. Cytokines
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are powerful regulators of the immune response and have
a significant role in the defense against pathogens.
Women with recurrent pyelonephritis have increased
levels of the cytokines IL-6 and IL-8 in their urine (35).
The major sources of these cytokines during UTI are the
bladder and kidney epithelium (36,37). The exact role
of IL-6 in the pathogenesis of UTI is unclear, although it
is known to amplify signals involved in neutrophil
recruitment (38) and enhance the maturation of B cells
into IgA-producing plasma cells (39). The production
of IL-8 by uroepithelial cells may be particularly
important in the transmigration of neutrophils across the
mucosal barrier in response to infection. In studies on
infected IL-8 receptor knockout mice, neutrophils became
trapped under the epithelium, apparently unable to cross
the epithelial barrier into the urinary tract lumen. The
delayed neutrophil influx rendered the mice highly
susceptible to UTI and the development of bacteriemia
(40). P fimbrial binding promotes cytokine production
by epithelial cells, therefore increasing the influx of
neutrophils into the kidneys of patients infected with P
fimbriated but not non-fimbriated strains (41). The
production of hemolysin also triggers transmembrane
signaling events that up-regulate IL-8 and IL-8 receptor-
specific mRNA (42). Lipopolysaccharide release activates
neutrophils, monocytes, and macrophages and further
stimulates the secretion of cytokines including IL-8.
BREACHING THE EPITHELIUM
Once bacteria have attached to the mucosal epithelium,
they can either colonize the surface or gain access to
deeper tissues by traversing the epithelial cell layer.
Bacteria can breach the epithelial barrier by gaining
access between cells, through cells, or by causing cell
shedding. As mentioned above, internalization of bacteria
into bladder cells leads to apoptosis and exfoliation of
bacteria-laden cells. However, although acting as a
defense mechanism by eradicating infected cells, it may
also help the bacteria establish a more persistent infection
by exposing the underlying cells. E. coli hemolysin may
act in a similar manner by directly causing death of the
target cell and providing a mechanism for the E. coli to
transverse the damaged epithelium (32). Alternatively,
bacteria can breach the epithelial defenses by entering
into the epithelial cells themselves. Studies in mice have
shown that bacteria persist in the bladder after exfoliation
as a result of bacterial internalization into the newly
exposed cells. Furthermore, once internalized, the
bacteria are able to survive and either replicate or persist
in a quiescent state, creating the opportunity for
reinfection–a common problem in patients with UTI
(43). Colony necrotizing factor has also been implicated
in causing internalization of E. coli into normally non-
phagocytic epithelial cells (44).
The entry of bacteria into cells can be achieved by
phagocytosis or by bacterial-induced endocytosis
(internalization). Up until 14 years ago, pyelonephritic
E. coli were considered exclusively extracellular
microorganisms. However, in 1988, Warren et al (45)
demonstrated internalization of E. coli into cultured
human proximal tubular cells. In the same year, E. coli
were observed in membrane-bound vesicles of both
phagocytic and epithelial cells in renal biopsies from
patients with acute pyelonephritis (46). Whereas
internalization of bacteria into phagocytes results in
bacterial degradation, internalization into a non-
phagocytic cell type allows the bacteria to enter a
nutrient-rich, protected environment where they can
avoid host defenses such as complement and professional
phagocytes. Interestingly, the type 1 adhesin FimH may
contribute to bacterial survival by subverting the normal
bactericidal function of macrophages. Normally, these
cells ingest and kill bacteria; however, adhesion to
macrophages via FimH directs the bacteria to non-
bactericidal compartments (47). It is therefore an
advantage to the bacteria to gain access into this protected
niche and the evidence suggests that bacteria have
devised various ways to achieve that goal.
Recent work in our laboratory suggests that pyelo-
nephritic bacteria may use a protein from the host
complement system to aid bacterial internalization and
increase renal infection (48) (Fig. 3). Mice genetically
deficient in the pivotal complement component C3 were
less susceptible to renal infection after inoculation of
pyelonephritic E. coli into the bladder. The presence of
C3 in the kidney therefore enhances renal colonization.
Furthermore, in vitro studies show that opsonization of
E. coli with C3 augments internalization of the bacteria
into murine proximal tubular cells and human
glomerular, tubular, and bladder epithelial cells. In
experimental models, mice with renal infection show
increased levels of C3 in the urine. The high molecular
weight of the C3 protein (185 000 kDa) makes it unlikely
to be filtered across the glomerular membrane from the
serum, and the more likely source is from renal cells
themselves. Within the kidney, several different cell types
are capable of producing C3, including proximal tubular
epithelial cells (PTECs). In vitro, the production of C3
by PTEC is up-regulated in the presence of LPS and this
is sufficient to augment E. coli internalization. However,
neutrophils and macrophages also produce C3 and may
therefore contribute to the availability of C3 for
opsonization. In this way, the inflammatory response
elicited by the bacteria may aid internalization into
PTECs.
Exploitation of host defense molecules to gain access to
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the intracellular environment is not uncommon. The
human immunodeficiency virus gains entry into cells via
the CD4 molecule on the cell surface (49) and
Streptococcus pneumonia invades activated endothelial
cells by binding to platelet-activating factor (50). Some
microorganisms specifically exploit complement proteins
to gain entry into cells. Leishmania major activates the
alternative pathway to deposit C3b on its surface. It is
then able to bind to CR type 1 (CR1), allowing it to enter
monocytes/macrophages where it replicates intra-
cellularly (51). Mycobacterium tuberculosis also
activates complement to enhance phagocytosis by
macrophages (52). Other microorganisms directly
interact with CRs to promote internalization. The
Epstein-Barr virus directly binds to CR2, mediating
internalization by B cells. Complement receptor type 2
has recently been identified on the renal epithelium (53),
providing a potential means for viral infection in the
kidney, the immune response against which could induce
tubulointerstitial nephritis. Urinary tract infection-
associated Dr fimbriae also directly interact with a
complement protein, DAF. The decay-accelerating factor
is a complement regulator that protects host cells from
complement-mediated lysis by binding and promoting
the catabolism of C3 and/or C4. The interaction of Dr
fimbriated E. coli with DAF activates intracellular
signaling pathways and cytoskeletal rearrangement that
results in internalization of the bacteria into membrane-
bound vacuoles.
CONCLUSIONS
Epithelial surfaces are continually exposed to potentially
pathogenic bacteria. Host defense mechanisms have
evolved to prevent infection; however, bacteria have
fought back, developing strategies to overcome these
defenses. Usually, the balance is in favor of the host, but
occasionally this balance shifts, permitting the
development of clinical infection. In the urinary tract,
renal colonization requires specialized structures that
promote ascent from the bladder and adhesion to the
uroepithelium. Once established, the bacteria may
enhance their own survival by internalizing into non-
phagocytic renal epithelial cells, an environment that is
both rich in nutrients and protected from the host defense
system. This could possibly lead to more severe infection,
or recurrent disease. Furthermore, abnormal or exuberant
host responses, particularly involving cytokines and
growth factors that are known to contribute to infiltration
and fibrosis, may lead to scar formation. Recent studies
suggest that opsonization of the bacteria by host C3
augments internalization of E. coli into renal cells. The
C3 deposited on the bacterial surface is likely to interact
with a receptor on the cell surface, inducing intracellu-
lar signaling pathways leading to cytoskeleton re-
arrangement and internalization of the bacteria. In the
balance between microbe and host, the susceptibility of
an individual to UTI may depend on the levels of C3
and/or the cell-surface receptor that they express. The
study of such interactions between the host epithelium
and the pathogen is still at an early stage. Much of our
current knowledge is based on the study of pathogen and
host factors in isolation. We are now moving to an era
when the interaction of these elements in living animals
is the focus of research. Advances in cellular and
molecular biology will allow the cellular mechanisms
of infection to be determined and thereby allow continued
development of strategies to prevent the development
of clinical infection.
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